NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $0.85 -0.05 (-5.96%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.84 -0.01 (-0.91%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Invivyd Stock (NASDAQ:IVVD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Invivyd alerts:Sign Up Key Stats Today's Range$0.82▼$0.9250-Day Range$0.47▼$0.9052-Week Range$0.35▼$2.74Volume1.51 million shsAverage Volume4.49 million shsMarket Capitalization$101.45 millionP/E RatioN/ADividend YieldN/APrice Target$5.85Consensus RatingBuy Company OverviewInvivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More… Invivyd Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreIVVD MarketRank™: Invivyd scored higher than 59% of companies evaluated by MarketBeat, and ranked 402nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 2 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($1.64) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.39% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently increased by 4.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.39% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently increased by 4.91%, indicating that investor sentiment is decreasing. News and Social Media1.7 / 5News Sentiment0.07 News SentimentInvivyd has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Invivyd this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Stock News HeadlinesHC Wainwright Cuts Invivyd (NASDAQ:IVVD) Price Target to $5.00May 29 at 2:01 AM | americanbankingnews.comInvivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 VirusMay 27 at 7:01 AM | globenewswire.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 29, 2025 | Premier Gold Co (Ad)Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell LymphomasMay 23, 2025 | globenewswire.comInvivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster EfficacyMay 23, 2025 | nasdaq.comInvivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19May 21, 2025 | globenewswire.comInvivyd's (IVVD) Buy Rating Reiterated at D. Boral CapitalMay 19, 2025 | americanbankingnews.comEarnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings missMay 16, 2025 | investing.comSee More Headlines IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $0.4431 at the beginning of the year. Since then, IVVD stock has increased by 90.9% and is now trading at $0.8457. View the best growth stocks for 2025 here. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) posted its earnings results on Thursday, May, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.10. The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Read the conference call transcript. Who are Invivyd's major shareholders? Top institutional shareholders of Invivyd include Maverick Capital Ltd. (9.14%), Redmile Group LLC (1.91%), Deutsche Bank AG (0.55%) and AQR Capital Management LLC (0.34%). View institutional ownership trends. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invivyd own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invivyd investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/15/2025Today5/28/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVVD CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$5.85 High Stock Price Target$9.00 Low Stock Price Target$3.55 Potential Upside/Downside+591.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.64 million Net MarginsN/A Pretax Margin-1,946.87% Return on Equity-155.33% Return on Assets-114.88% Debt Debt-to-Equity RatioN/A Current Ratio1.92 Quick Ratio1.58 Sales & Book Value Annual Sales$36.69 million Price / Sales2.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book0.53Miscellaneous Outstanding Shares119,961,000Free Float98,205,000Market Cap$101.45 million OptionableOptionable Beta0.40 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:IVVD) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.